EndoC-BH1 Human Beta Cells for HTS and Diabetes Drug Discovery

In the most comprehensive independent evaluation of the human beta cell line EndoC-βH1 conducted to date, a publication co-authored by lead pharmacologists and drug development experts at Novo Nordisk revealed EndoC-βH1 to be a very valuable and highly relevant tool for studying Diabetes.
The study entitled,”The EndoC-βH1 cell line is a valid model of human beta cells and applicable for screenings to identify novel drug target candidates” was published online December 2017 in Molecular Metabolism. Dr. Thomas Frogne, Specialist, Islet & Stem cell Biology at Novo Nordisk is the last author on the publication.

GSIS assays (Glucose Stimulated Insulin Secretion) have been the “gold-standard” for determining the functionality of a beta cell. Study of dynamic insulin release with perfusion assays is a crucial component of beta cell research. Up to now, heterogeneity in islet size and composition decreased experimental resolution, limits reproducibility and capability of using human islets for medium or large throughput GSIS screening and assay modeling. Both scientists from academia and industry are looking for large quantity of robust and functional human beta cells.

There is a growing need for better predictive tools to assess human beta cell dysfunction early in the drug development process. The authors at Novo Nordisk note in their publication, that “they have now successfully used EndoC-βH1 as a screening platform for early drug discovery with regards to insulin secretion and beta cell proliferation and identified several interesting peptides and proteins.” According to the authors from Novo Nordisk their study determined that the EndoC-βH1 “is also of interest for screening compounds with beneficial effect on ER stress” and more globally EndoC-βH1 “can be efficiently applied as a screening platform for novel anti-diabetic drug candidates with the aim of achieving higher probability of the candidates to show an effect on real human beta cells”.

This independent study published in an international top level journal provides convincing, independent evidence that the EndoC-βH1 represents a unique tool to identify innovative therapeutics approaches. “Having a world’s leading pharmaceutical company in the field of Diabetes Drug Discovery to produce this thorough validation further confirms that our EndoC-βH1 not only reflects human beta cell biology, but also delivers the reproducibility and scalability required to meet the screening demands of large pharma” says Guillaume Costecalde, Chairman of Univercell-Biosolutions.

EndoC-βH1 is an immortalized human beta cell line developed by Univercell-Biosolutions that displays an enhanced beta cell phenotype, metabolic activity, and stability over 100 passages i.e. 2 years.

For more information about the EndoC-βH1 human beta cell and its applications, don’t hesitate to visit the Univercell Biosolutions website.